As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.
On September 30, the semaglutide injection developed by Bejing Peptide was officially accepted by CDE.
On October 5, Bejing Peptide's ZT002 completed the administration of the first participants in Phase I clinical trials in Australia.
Under the guidance of the innovation strategy, the R&D pipeline of Bejing Peptide has been advanced efficiently and the results have been continuous, which reflects the outstanding ability of Bejing Peptide in the field of innovative research and development in the field of metabolic diseases.
As a partner of Bejing Peptide, Shanghai Medicilon Inc. provides a full set of preclinical research services for Bejing Peptide semaglutide Injection. Medicilon also provides the pharmacology services to ZT002 that comply with the application in China, US and Australia.
As one of the few biopharmaceutical preclinical research companies with comprehensive service capabilities in the CRO industry in China, Medicilon has been catching up with innovation, insight and the latest technological development for 18 years, building a technical service platform for the development direction of global innovative drugs, and helping to accelerate the registration and declaration of new drugs. The Medicilon clinical registration affairs service platform has a professional IND and ANDA research team, which has an in-depth understanding of the registration regulations and policies of China, the United States, Australia, the European Union and other countries and regions, as well as the technical requirements for chemical drugs. Medicilon can provide clients in China with NMPA IND declaration and US FDA IND/ANDA declaration services, and can provide NMPA IND/ANDA declaration services for foreign clients. Medicilon can customize a practical registration strategy, avoid potential registration risks, ensure timely and accurate submission of application materials, and track the review progress to help clients quickly complete the registration review process.
About Beijing Peptide
Beijing Peptide is a innovative drug company in the clinical development stage, dedicated to the development of innovative biological drugs for the treatment of metabolic diseases. Driven by originality, the independent intellectual property technology platform of Beijing Peptide covers the complete recombinant protein production process. Beijing Peptide is in an international leading position in many aspects such as engineering bacteria transformation, drug design, inclusion body expression, renaturation, protein purification, modification, fusion protein, oral protein drug and other production process development and amplification.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the mid 2022, Medicilon has provided new drug R&D services to more than 1,710 clients around the world, and participated in the R&D of 268 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
Share：
Relevant News
marketing@medicilon.com
ABOUT
